IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

APPLICANTS:

Maurer et al

DOCKET NO.:

112843-006

SERIAL NO:

09/674,738

ART UNIT:

Unknown

FILED:

November 3, 2006 ENT &

EXAMINER:

Unknown

INVENTION:

"USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD

COAGULATION"

Assistant Commissioner for Patents

Washington, D.C. 20231

SIR:

In accordance with the provisions of 37 C.F.R. 1.56, Applicants request that a citation and examination of the references identified below and on the attached PTO-1449 form be made during the course of examination of the above-mentioned application for United States Patent.

Foreign Patent Number	Country	Publication Date
JP 63 295515 A	Japan	January 12, 1988
43 02 060 A1	Germany	July 28, 1994
WO 95/00169	PCT	January 5, 1995
WO 98/38291	PCT	September 3, 1998

Other Publications

Sunny, et al., "Effect of Fabrication, Sterilization and Mediators – Blood Compatibility of Polyurethanes", J. of Biomaterials Applications, Volume 6, January 1992, pp 261-273.

Harrach, et al., "Isolation and Partial Characterization of Basic Proteinaases from Stem Bromelain", J. of Protein Chemistry, Vol. 14, No. 1, 1995, pp. 41-52.

Taussig, et al., "Bromelain, the Enzyme Complex of Pineapple and its Clinical Application, an Update", J. of Ethnopharmacology, Vol. 22, 1998, pp 191-203.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

(Reg. No. 30,142)

Robert M. Barrett

BELL, BOYD & LLOYD LLC

P.O. Box 1135

Chicago, Illinois 60690-1135

(312) 807-4204

ATTORNEY FOR APPLICANTS

522 Raid PCT/PTO 0 2 BAN 21

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Docket No.

(Under 37 CFR 1.97(b) or 1.97(c)) 112843-006 In Re Application Of: Maurer et al. Filing Date Examiner Group Art Unit Serial No. 09/674,738 November 3, 2000 Unknown Unknown Title: USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD COAGULATION Address to **Assistant Commissioner for Patents** Washington, D.C. 20231 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing 1. 🛛 of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after three months of the filing of 2. a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113, or 2. a Notice of Allowance under 37 CFR 1.311, whichever occurs first. Also submitted herewith is: a certification as specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

1	INFORMATION DISCLO		Docket No. 112843-006	
In Re Application Of: M	Taurer et al.	JAN 0 2 2001 3		
Serial No. 09/674,738	Filing Date November 3, 2000	Examinatent & TRADE	Group Art Unit Unknown	
Title: USE OF BROMELAINE	PROTEASES FOR INHIBITING	S BLOOD COAGULATION		
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of Credit any overpayment. Charge any additional fee required. Certificate of Transmission by Facsimile* Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail Certificate of Mailing by First Class Ma				
cc:				